Q-omics provides the consensus-scored ARHGEF26 profile across patient tissues and cancer cell-line models. ARHGEF26 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARHGEF26 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ARHGEF26 RNA expression shows 20,594 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where ARHGEF26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF26 survival associations across molecular data types. ARHGEF26 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF26 RNA expression–survival associations across cancer types. High ARHGEF26 expression shows unfavorable associations in MESO and KICH, but favorable associations in OV, HNSC, PAAD and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ARHGEF26 RNA expression.
This table summarizes ARHGEF26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGEF26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF26 shows lower tumor expression in KIRC, LUAD, BLCA, LUSC, LIHC and COAD. The KIRC box plot shows higher ARHGEF26 RNA expression in normal versus tumor tissue (log2 FC = −1.154, t-test p < 0.001).
This table shows molecular features associated with ARHGEF26 in patient tissues and cancer cell lines. In patient samples, ARHGEF26 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGEF26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
